Radiosurgery & Radiation Therapy for Pituitary Tumors | NYU Langone Health
NYU Langone doctors may use radiosurgery or radiation therapy to manage some pituitary tumors.
Randomized Controlled Open-Label Parallel Group Multi-Center Prospective Phase 4 Study Comparing the Efficacy of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2 3 and 4 Pressure Injuries
This research is studying a powder wound dressing called Altrazeal®, also called Transforming PowderDressing (TPD). TPD will be used in this study to treat pressure injuries and will be compared totreatment of pressure injuries using the normal care, also called Standard of Care (SOC) used by yourhealth care provider. When you have a pressure injury, or open wound caused by pressure, your doctorwill treat it using some type of dressing. There are many types of dressing, including gauze, films, foams,and others. This research will specifically focus on the effect TPD has on the number of dressing changes,as compared to the currently used SOC treatment. All subjects in this study will receive study treatmenteither with TPD or with another type of commonly used dressing under current standard of careguidelines.
Randomized Double-blind Placebo-Controlled Multicenter Phase 3 Study to Evaluate the Safety Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures
In this research a study drug named XEN1101 is being tested for the treatment of seizures. XEN1101 is a study drug because its safety, effectiveness, and/or how it works is/are still being studied. XEN1101 has not been approved for commercial use by government health authorities in any country, as a treatment for any condition. The main purpose of this study is to determine if XEN1101 can reduce the seizure frequency and if it is safe to use. XEN1101 has been tested in other studies in epilepsy patients and it was considered to be well-tolerated. It had side effects that are similar to other antiseizure drugs commonly used to help patients with epilepsy. The study will compare XEN1101 to a placebo to see if XEN1101 is safe and works better than the placebo.
RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 2 STUDY OF VE202 IN PATIENTS WITH MILD-TO-MODERATE ULCERATIVE COLITIS
This is a phase 2 double-blind, placebo-controlled, randomized study to evaluate the safety, efficacy, and microbiota changes of VE202 in biologic-naïve patients with mild to moderate Ulcerative Colitis (UC). The duration of the study for each study patient is approximately 56 weeks (up to 4 weeks for screening and vancomycin pretreatment, and 52 weeks from the time of the first dose of VE202 or placebo until completion of the last follow-up visit).
Randomized Double-Blind Placebo-Controlled Study to Evaluate the Effects of EP547 in Subjects with Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis
Intense. Unrelenting. Distressing. Itching. If you have itch due to liver disease, consider participating in pruritus research. The PACIFIC study is testing an investigational drug (EP547) to see if it can help reduce itch (pruritus) in adults with Primary Biliary Cholangitis (PBC) or Primary Sclerosing Cholangitis (PSC). By participating in this study, you may be helping to advance development of a potential new treatment.Every day, research uncovers new information about medical conditions and their potential treatments. Volunteer involvement in clinical studies from participants like you, especially in rare diseases, is critical to advance development of future therapies. Results collected from clinical studies have led to thousands of medications becoming available to patients all over the world.
Randomized multicenter open-label phase 3 study of mirvetuximab soravtansine in combination with bevacizumab versus bevacizumab alone as maintenance therapy for patients with FRa-positive recurrent platinum-sensitive ovarian cancer
This study is designed for patients diagnosed with FRa-positive recurrent platinum-sensitive epithelial ovarian, fallopian tube, or primary peritoneal cancers after second line platinum-based chemotherapy plus bevacizumab. The purposes of this study are: To determine if mirvetuximab soravtansine (MIRV) plus BEV is effective at keeping ovarian cancer from relapsing in patients recurrent platinum sensitive ovarian cancer cancer iafter chemotherapy in the maintenance setting (meaning to assess if it helps to prevent their cancer from returning or delaying their cancer’s return). To determine if mirvetuximab soravtansine (MIRV) plus BEV is more effective at managing patients with ovarian cancer and maintenance setting than treatment with BEV alone. To find out what side effects, both good and/or bad, MIRV plus BEV may have on patients with ovarian cancer. To assess if taking MIRV and BEV affects quality of life, both good and/or bad.
Randomized Phase 2 Study of DKN-01 Plus FOLFIRI/FOLFOX and Bevacizumab Versus FOLFIRI/FOLFOX and Bevacizumab as Second-line Treatment of Advanced Colorectal Cancer (DeFianCe)
This study is testing a new treatment for patients with advanced colorectal cancer (CRC) who need a second round of treatment. They want to see if adding a drug called DKN-01 to the usual treatment, which includes two different chemotherapy drugs (FOLFIRI/FOLFOX) and another medicine called bevacizumab, works better than just the usual treatment alone. Patients with advanced CRC, whose cancer has gotten worse after trying one type of treatment, will join the study. They will go through different stages with the study team, including checking their health, receiving the treatment, and then keeping an eye on their health afterward to see how the patients are doing and if the cancer gets worse. The study team will also watch those who stop treatment for reasons not related to cancer to see if their cancer comes back.
RANDOMIZED PHASE II/III TRIAL OF SENTINEL LYMPH NODE BIOPSY VERSUS ELECTIVE NECK DISSECTION FOR EARLY-STAGE ORAL CAVITY CANCER
The purpose of the study is to compare Elective Neck Dissection (END) and Sentinel Lymph Node (SLN) Biopsy in terms of shoulder related-quality of life (QOL) and disease-free survival (DFS) in patients with early-stage oral cavity squamous cell carcinoma (OCSCC) (cT1-2N0). This study is being done to answer the following questions: 1) will neck and shoulder function and discomfort be better if you have a procedure called sentinel lymph node (SLN) biopsy instead of the usual surgery for this type of cancer; and 2) is SLN biopsy the same as the usual surgery in extending the time you have without cancer returning? One of two types of imaging agents, Lymphoseek (tilmanocept) or sulfur colloid, may be used in the SLN biopsy depending on your doctor’s preference. Lymphoseek is approved by the Food and Drug Administration (FDA) for locating lymph nodes for your type of cancer. Sulfur colloid is not FDA approved for oral cavity cancer, but it is approved for locating lymph nodes in other types of cancer.
Randomized Placebo-Controlled Trial to Determine the Biological Signature of Cannabidiol as a Treatment for Social Anxiety Disorder
The purpose of this research study is to determine whether cannabidiol (CBD), a non-psychoactive part of cannabis, is an effective treatment for social anxiety disorder (SAD), and to better understand how CBD might improve SAD symptoms. After medical and psychiatric evaluations are completed, eligible participants are randomly assigned (that is, by chance) to one of two treatments lasting approximately 3 weeks: CBD or placebo. The study will last about 1-2 months and full participation includes 6 study visits as well as fMRI neuroimaging scans, a stress task, and blood tests. Eligible participants receive compensation for time completing study assessments.
Randomized Study of ONC-392 plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) who Progressed on Androgen Receptor (AR) Pathway Inhibition
This study wants to see if a new immunotherapy treatment called ONC-392, combined with Lu 177 vipivotide (Pluvicto) compared to Lu 177 vipivotide (Pluvicto) alone, can help people with metastatic castration-resistant prostate cancer (mCRPC). The people in the study have already tried one kind of treatment that didn't work (prior androgen receptor-targeted therapy, ARTA), and they haven't had Lu 177 vipivotide before. The study will start by testing different dosage amounts of ONC-392 to find the safest one to use with Lu 177 vipivotide. After that, they'll give the highest dose with few side effects to more people to see if it works well. Patients will be monitor for side effects, undergo imaging (scans), and undergo blood tests regularly. The study will also keep track of cancer control, patient survival, and side effects.